| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CBR4 |
| Uniprot No | Q8N4T8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-237aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMDKVCAVFGGSRGIGRAVAQLMARKGYRLA VIARNLEGAKAAAGDLGGDHLAFSCDVAKEHDVQNTFEEMEKHLGRVNFL VNAAGINRDGLLVRTKTEDMVSQLHTNLLGSMLTCKAAMRTMIQQQGGSI VNVGSIVGLKGNSGQSVYSASKGGLVGFSRALAKEVARKKIRVNVVAPGF VHTDMTKDLKEEHLKKNIPLGRFGETIEVAHAVVFLLESPYITGHVLVVD GGLQLIL |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CBR4重组蛋白的模拟参考文献示例(注：以下内容为虚构示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*Heterologous Expression and Functional Characterization of Recombinant Human CBR4 in E. coli*
**作者**：Zhang, L., et al.
**摘要**：本研究成功在大肠杆菌中表达了重组人源CBR4蛋白，并通过亲和层析纯化获得高纯度产物。酶活实验表明，重组CBR4对多种羰基类化合物(如异源前列腺素)具有显著还原活性，提示其在药物代谢中的潜在作用。
2. **文献名称**：*Crystal Structure Analysis of CBR4 Reveals Substrate-Binding Mechanisms*
**作者**：Smith, J.R., et al.
**摘要**：通过X射线晶体学解析了CBR4的三维结构(分辨率2.1 Å)，发现其活性口袋含有保守的NADPH结合域。分子对接实验进一步揭示了CBR4与抗癌药物阿霉素的相互作用，为设计特异性抑制剂提供了结构基础。
3. **文献名称**：*Role of Recombinant CBR4 in Chemoresistance of Hepatocellular Carcinoma*
**作者**：Lee, H., et al.
**摘要**：在肝癌细胞中过表达重组CBR4后，研究者观察到细胞对顺铂的耐药性显著增强。机制研究表明，CBR4通过代谢药物毒性中间体降低细胞内活性氧水平，从而促进癌细胞存活。
4. **文献名称**：*Development of CBR4 Inhibitors Using High-Throughput Screening with Recombinant Protein*
**作者**：Brown, K., et al.
**摘要**：利用重组CBR4蛋白建立高通量筛选平台，鉴定出小分子化合物CX-1023可有效抑制CBR4酶活(IC50=0.8 μM)。动物实验表明，CX-1023可增强化疗药物在肿瘤模型中的疗效。
---
如需实际文献，建议在PubMed、Web of Science等平台以“CBR4 recombinant protein”“Carbonyl reductase 4 expression”等关键词检索。
**Background of CBR4 Recombinant Protein**
CBR4 (Carbonyl Reductase 4) is a member of the short-chain dehydrogenase/reductase (SDR) superfamily, which plays a role in metabolizing endogenous and exogenous carbonyl-containing compounds. This enzyme catalyzes the NADPH-dependent reduction of various ketones, quinones, and lipid peroxidation-derived aldehydes, contributing to cellular detoxification and redox homeostasis. CBR4 is ubiquitously expressed, with notable activity in tissues such as the liver, kidney, and brain, though its precise physiological substrates remain under investigation.
Structurally, CBR4 shares a conserved Rossmann-fold motif typical of SDR enzymes, with a catalytic triad (Ser-Tyr-Lys) critical for its enzymatic activity. Unlike other carbonyl reductases (e.g., CBR1 or CBR3), CBR4 exhibits distinct substrate specificity and subcellular localization, primarily residing in the cytoplasm. Emerging studies suggest its involvement in lipid metabolism, steroid hormone regulation, and protection against oxidative stress, linking it to pathologies such as metabolic disorders, neurodegenerative diseases, and cancer.
Recombinant CBR4 protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells*) to enable functional and structural studies. Its production typically involves codon optimization, affinity tag fusion (e.g., His-tag), and purification via chromatography. Recombinant CBR4 serves as a tool to dissect substrate preferences, inhibitor screening for therapeutic development, and elucidating mechanisms underlying drug resistance (e.g., in anthracycline chemotherapy).
Despite progress, gaps remain in understanding CBR4's endogenous roles, regulatory pathways, and potential as a biomarker or drug target. Ongoing research aims to clarify its contributions to cellular metabolism and disease, leveraging recombinant protein technology for mechanistic and translational insights.
×
